Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. develops clinical-stage cancer therapeutics, with news centered on micvotabart pelidotin, or MICVO, an investigational antibody-drug conjugate targeting extradomain-B fibronectin in the tumor extracellular matrix. Company updates focus on MICVO in solid tumors, including recurrent or metastatic head and neck squamous cell carcinoma, and on monotherapy and pembrolizumab combination development.
Recurring developments include clinical and preclinical data presentations, translational research on MICVO’s mechanism of action, quarterly and annual financial results, corporate presentations, leadership changes, business development appointments, and capital actions tied to funding the company’s oncology pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On March 31, 2023, Pyxis Oncology (Nasdaq: PYXS) announced the granting of restricted stock units totaling 54,010 shares and stock options for 67,513 shares to three new employees as part of its 2022 Inducement Plan. The vesting of these awards occurs over four years, with 25% vesting on the first anniversary, followed by monthly vesting for 36 months. The stock options feature a ten-year term with an exercise price of $4.01, reflecting the closing stock price on the grant date. This move aligns with Nasdaq Listing Rule 5635(c)(4), aimed at attracting talent to advance the company's mission against difficult-to-treat cancers.
Pyxis Oncology (Nasdaq: PYXS) reported full-year 2022 financial results and updates on its clinical trials. The company has initiated two Phase 1 trials for its candidates PYX-201 and PYX-106, with preliminary data expected by early 2024. As of year-end 2022, Pyxis maintained a strong balance sheet with $180.7 million in cash and no debt, funding operations into 1H 2025. Research and development expenses rose to $86.1 million, while general and administrative costs increased to $37.4 million, leading to a net loss of $120.7 million for 2022, equating to ($3.65) per share. The company also received FDA clearance for both candidates' INDs.